The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma.
Fei XuePeihao ZhengRui LiuShaomei FengYuelu GuoHui ShiHaidi LiuBiping DengTeng XuXiaoyan KeKai HuPublished in: Journal of oncology (2022)
The CAR T-cell therapy could augment its efficacy in the treatment of advanced relapsed/refractory CNS B-cell lymphoma, while ASCT in combination with CART can induce durable responses and OS with a manageable side effect.
Keyphrases
- cell therapy
- diffuse large b cell lymphoma
- acute lymphoblastic leukemia
- acute myeloid leukemia
- stem cells
- mesenchymal stem cells
- induced apoptosis
- multiple myeloma
- hodgkin lymphoma
- cell cycle arrest
- blood brain barrier
- type diabetes
- oxidative stress
- signaling pathway
- combination therapy
- metabolic syndrome
- cell proliferation